Literature DB >> 33482325

Epigenetics and microRNAs in cardiovascular diseases.

Robin M W Colpaert1, Martina Calore2.   

Abstract

Cardiovascular diseases are among the leading causes of mortality worldwide. Besides environmental and genetic changes, these disorders can be influenced by processes which do not affect DNA sequence yet still play an important role in gene expression and which can be inherited. These so-called 'epigenetic' changes include DNA methylation, histone modifications, and ATP-dependent chromatin remodeling enzymes, which influence chromatin remodeling and gene expression. Next to these, microRNAs are non-coding RNA molecules that silence genes post-transcriptionally. Both epigenetic factors and microRNAs are known to influence cardiac development and homeostasis, in an individual fashion but also in a complex regulatory network. In this review, we will discuss how epigenetic factors and microRNAs interact with each other and how together they can influence cardiovascular diseases.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular diseases; Epigenetics; Heart; miRNAs

Mesh:

Substances:

Year:  2021        PMID: 33482325     DOI: 10.1016/j.ygeno.2020.12.042

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  10 in total

Review 1.  Targeting the cytoskeleton and extracellular matrix in cardiovascular disease drug discovery.

Authors:  Bohdan B Khomtchouk; Yoon Seo Lee; Maha L Khan; Patrick Sun; Deniel Mero; Michael H Davidson
Journal:  Expert Opin Drug Discov       Date:  2022-03-08       Impact factor: 7.050

Review 2.  The role of non-coding RNAs in myocarditis: a narrative review.

Authors:  Wenhu Liu; Jing Hu; Shuai Lu; Zhaohui Wang
Journal:  Ann Transl Med       Date:  2022-09

Review 3.  A Non-Canonical Link between Non-Coding RNAs and Cardiovascular Diseases.

Authors:  Lucia Natarelli; Christian Weber
Journal:  Biomedicines       Date:  2022-02-14

4.  miRNA Profile Based on ART Delay in Vertically Infected HIV-1 Youths Is Associated With Inflammatory Biomarkers and Activation and Maturation Immune Levels.

Authors:  Laura Tarancon-Diez; Irene Consuegra; Elena Vazquez-Alejo; Ricardo Ramos-Ruiz; José Tomás Ramos; María Luisa Navarro; Mª Ángeles Muñoz-Fernández
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

Review 5.  Epigenetics and Heart Development.

Authors:  Rajani M George; Anthony B Firulli
Journal:  Front Cell Dev Biol       Date:  2021-05-06

6.  Dissecting miRNA-Gene Networks to Map Clinical Utility Roads of Pharmacogenomics-Guided Therapeutic Decisions in Cardiovascular Precision Medicine.

Authors:  Fani Chatzopoulou; Konstantinos A Kyritsis; Christos I Papagiannopoulos; Eleftheria Galatou; Nikolaos Mittas; Nikoleta F Theodoroula; Andreas S Papazoglou; Efstratios Karagiannidis; Maria Chatzidimitriou; Anna Papa; Georgios Sianos; Lefteris Angelis; Dimitrios Chatzidimitriou; Ioannis S Vizirianakis
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

Review 7.  Lupus nephritis: The regulatory interplay between epigenetic and MicroRNAs.

Authors:  Ning Xu; Jie Liu; Xiangling Li
Journal:  Front Physiol       Date:  2022-09-16       Impact factor: 4.755

Review 8.  Update in Biomolecular and Genetic Bases of Bicuspid Aortopathy.

Authors:  Alejandro Junco-Vicente; Álvaro Del Río-García; María Martín; Isabel Rodríguez
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

9.  Downregulation of miR-181a-5p alleviates oxidative stress and inflammation in coronary microembolization-induced myocardial damage by directly targeting XIAP.

Authors:  You Zhou; Man-Yun Long; Zhi-Qing Chen; Jun-Wen Huang; Zhen-Bai Qin; Lang Li
Journal:  J Geriatr Cardiol       Date:  2021-06-28       Impact factor: 3.327

Review 10.  miRNAs in Cardiac Myxoma: New Pathologic Findings for Potential Therapeutic Opportunities.

Authors:  Antonio Nenna; Francesco Loreni; Omar Giacinto; Camilla Chello; Pierluigi Nappi; Massimo Chello; Francesco Nappi
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.